Señales en vivo de ACXP | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	28 594.00
Volumen promedio	99 434.00
Capitalización de mercado	32.62M
EPS	$-0.380 ( 2024-03-18 )
Próxima fecha de ganancias	( $-0.240 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.800
ATR14	$0.0140 (0.68%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-23	Luci David P	Buy	250 000	Stock Option
2024-02-23	Shawah Robert G.	Buy	145 000	Stock Option
2024-02-23	Deluccia Robert J	Buy	250 000	Stock Option
2024-01-19	Sailer Carl	Buy	19 737	Common Stock
2024-01-19	Sailer Carl	Sell	19 737	Warrants for Common Stock

INSIDER POWER
76.75
Last 61 transactions
Buy: 3 435 791 \| Sell: 229 212

Volumen Correlación

Largo: 0.26 (neutral)

Corto: 0.65 (weak)

Signal:(59.834) Neutral

Acurx Pharmaceuticals, Correlación

10 Correlaciones Más Positivas
SISI	0.968
GLMD	0.965
PEAR	0.963
GMBL	0.962
PPBT	0.951
LAWS	0.948
ACET	0.945
PTE	0.944
NCBS	0.944
CYTO	0.942

10 Correlaciones Más Negativas
GXII	-0.969
CLBT	-0.961
GASS	-0.958
ISEE	-0.958
RAM	-0.957
MITA	-0.957
NECB	-0.956
IVCB	-0.955
AGGR	-0.955
CSWC	-0.954

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Acurx Pharmaceuticals, Correlación - Moneda/Commodity

-0.20
( neutral )

-0.30
( neutral )

0.00
( neutral )

0.02
( neutral )

0.00
( neutral )

-0.01
( neutral )

Acurx Pharmaceuticals, Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-1.150

FY	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-1.150

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-1.120

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Acurx Pharmaceuticals,

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.